1650results about "Dragees" patented technology

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention discloses an abesilil raw material medicine, a composition, a tablet and a preparation method thereof. The particle size distribution of the abesilil raw material medicine is as follows: D10 is more than or equal to 20 microns, D90 is more than or equal to 60 microns and less than or equal to 300 microns, and the span (D90-D10) / D50 is less than or equal to 2.5. According to the present invention, the large raw material particle size within a certain range is provided, the dissolution rate and the dissolution amount of the abelsilil tablet in the pH 6.8 medium can be easily improved, the sticking phenomenon during the tabletting process can be solved, the production process is simple, the production period is short, the production cost is low, the mixing and the tabletting are smooth, and the dissolution end point is high.

The invention provides an extraction method of hirudin, an oral preparation containing the hirudin and a preparation method of the oral preparation, and belongs to the technical field of leech processing and traditional Chinese medicine. The hirudin extraction method comprises the following steps: S1, soaking fresh leeches in a freeze-drying protective agent, taking out the leeches, wiping the surfaces of the leeches, pre-freezing the leeches at the temperature of 40 DEG C below zero to 50 DEG C below zero for 1-2 hours, and freeze-drying the leeches at the temperature of 20 DEG C below zero to 30 DEG C below zero for 4-6 hours to obtain freeze-dried leeches; s2, crushing the freeze-dried leeches, adding the crushed leeches into water, adding enzyme and lecithin, performing enzymolysis for 4-6 hours under the conditions that the temperature is 35-40 DEG C and the pH value is 7.5-8.5, and cooling to room temperature to obtain an enzymolysis product; s3, sterilization, ultrafiltration and drying are conducted, and hirudin is obtained. The hirudin extracted by the method is high in activity and high in recovery rate.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a melogabalin besylate tablet containing a stabilizer and a preparation method of the melogabalin besylate tablet. The melogaba besylate tablet containing the stabilizer comprises a coating and a tablet core, wherein the tablet core comprises the following components: melogaba besylate, the stabilizer, a disintegrating agent, a lubricating agent and the balance of a filling agent; and the coating is prepared from the following materials: an Intai W100 film coating premixing agent and acrylic resin IV. The filling agent comprises xylitol, pregelatinized starch and maltodextrin in a mass ratio of (3-4): 3: (1-2). The stabilizer is vitamin E succinic acid polyethylene glycol ester. The coating is prepared from the following materials: an Intai W100 film coating premixing agent and acrylic resin IV in a mass ratio of (1-1): (1-2). According to the melogabalin besylate tablet prepared by the invention, the stability and the dissolution performance can be synchronously improved.

There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 5 kDa or more, the polymer matrix containing a hydrophobic polymer. The membrane polymer matrix includes from about 70 wt. % to about 99 wt. % of an ethylene vinyl acetate copolymer.

The invention discloses a sustained-release pill as well as a preparation method and application thereof, and belongs to the technical field of medicines. The sustained-release pill comprises a pill core and a coating layer coated outside the pill core, the pellet core is prepared from the following raw materials in parts by mass: 8 to 14 parts of loxoprofen sodium, 30 to 60 parts of a filling agent, 3 to 10 parts of an adhesive, 2 to 10 parts of a disintegrating agent, 0.1 to 2 parts of a penetration enhancer, 0.05 to 0.2 part of a pH regulator, 0.1 to 0.5 part of a surfactant and 0 to 20 parts of an auxiliary agent; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin. Aiming at the drug characteristics of loxoprofen sodium, the loxoprofen sodium sustained-release tablet is composed of specific auxiliary materials, the drug composition is optimized, the drug release rate is accurately controlled, the bioavailability and stability of the drug are effectively improved, and the loxoprofen sodium sustained-release tablet has a good application prospect in preparation of antipyretic and analgesic drugs.

The present invention discloses a tofacitinib citrate sustained-release tablet preparation and a preparation method thereof, which belongs to the technical field of pharmaceutical preparations. The sustained-release tablet comprises a double-layer core and a coating layer; the double-layer core comprises a drug-containing layer and a push layer; wherein the drug-containing layer comprises: tofacitinib citrate, an adhesive, polyethylene oxide, a glidant and a lubricant; the push layer comprises: mannitol, an adhesive, red iron oxide, polyethylene oxide, a glidant and a lubricant; the coating layer comprises: cellulose acetate, a pore-forming agent, a plasticizer, water and acetone. The sustained-release tablet preparation of the present invention solves the technical problems existing in the prior art by adopting a double-layer osmotic pump prescription design, adopting non-hygroscopic materials such as mannitol, adopting a standard round tablet design, preparing a sustained-release coating layer without using methanol, and adopting a coating machine for coating and curing.

The present invention concerns pharmaceutical formulations of apalutamide, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for improving obesity and metabolic syndrome and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 28 parts of radix astragali seu hedysari, 8 to 20 parts of radix codonopsis, 20 to 35 parts of rhizoma dioscoreae, 8 to 24 parts of semen lablab album, 6 to 20 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 20 to 35 parts of raw semen coicis, 3 to 10 parts of rhizoma pinelliae preparata, 6 to 15 parts of pericarpium citri reticulatae, 10 to 20 parts of poria cocos, 6 to 15 parts of rhizoma alismatis, 6 to 15 parts of raw liquorice root, 10 to 20 parts of semen hoveniae, 10 to 20 parts of lotus leaf and 8 to 15 parts of raw fructus crataegi. The composition has the effects of invigorating spleen, replenishing qi, resolving dampness and removing turbidity, can effectively control the weight gain of obese patients and improve the metabolic disorder condition of metabolic syndrome, is safe, effective and stable, has small side effects, and has very good research and development values.

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

The invention discloses an oral sleep-aiding composition containing ergothioneine and a preparation method of the oral sleep-aiding composition, and relates to the technical field of sleep-aiding compositions. The oral sleep-aiding composition containing the ergothioneine is prepared from the following components in parts by mass: 0.01 to 3 parts of the ergothioneine, 0.1 to 10 parts of melatonin, 10 to 40 parts of glycine, 2 to 15 parts of magnesium salt, 30 to 70 parts of a diluent, 1 to 10 parts of an adhesive, 0.5 to 5 parts of a lubricant, 2 to 10 parts of a disintegrating agent and 0.1 to 0.5 part of an antioxidant preservative. Through the synergistic compatibility of ergothioneine, melatonin, glycine and magnesium salt, a multi-dimensional action network of oxidation resistance, neuromodulation and receptor inhibition is formed, the limitation of single-component sleep aiding is broken through, and the sleeping efficiency and the sleep maintenance capability are remarkably improved. Based on the scientific proportion of endogenous substances (ergothioneine and glycine), the metabolic burden of traditional sleep-aiding components is avoided, and in combination with the design of a sustained-release preparation, the dose-dependent side effects are reduced, and the safety of long-term taking is improved.

The invention relates to the field of pharmaceutical preparations, and particularly discloses an amorphous-state tigorazan tablet and a preparation method thereof. The amorphous-state tigorazan tablet comprises a tablet and a coating material in a weight ratio of 100: (2-4), the tablet comprises the following raw materials: amorphous-state tigorazan, a carrier inclusion material, an excipient, a disintegrating agent, a lubricant and a flow aid, the dosage of the amorphous-state tigorazan is 20-30% of the total mass of all the raw materials of the tablet, and the dosage of the carrier inclusion material is 20-30% of the total mass of all the raw materials of the tablet. The weight ratio of the amorphous tigoran to the carrier inclusion material is 1: (0.80-1.15), and the carrier inclusion material is vitamin E polyethylene glycol succinate. The amorphous tigorazan tablet provided by the invention not only has higher solubility and dissolution rate, but also has higher stability and better hardness and friability, not only improves the bioavailability of drugs, but also avoids the use of organic solvents, simplifies the production process, reduces the risks of production safety and environmental protection, and is suitable for large-scale industrial production.

To provide crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), dosage forms comprising the same, and methods of using the same for treatment.SOLUTION: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also there are disclosed pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.SELECTED DRAWING: None

The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).

A unit dosage of an oral composition of an extract of Withania somnifera is disclosed. The extract of Withania somnifera includes total withanolides. The total withanolides includes withanolide glycosides and withanolide aglycones. The extract of Withania somnifera includes about 32% to about 38% by weight of the withanolide glycosides. Methods of preparing the extract of Withania somnifera are disclosed. Methods of treatment by administering the extract of Withania somnifera are disclosed.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The invention discloses a tigorasan hot-melt extrudate as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The tigorasan hot-melt extrudate comprises the following raw materials: tigorasan and a carrier material in a mass ratio of 1: 11-2: 3. The solid preparation prepared from the hot-melt extrudate has the characteristics of good stability and high dissolution rate.

The invention provides a pharmaceutical composition for bone joints as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition is prepared from the following components in parts by weight: 20 to 2000 parts of N-acetylglucosamine and 10 to 1000 parts of non-denatured type II collagen. In the compound composition of the N-acetylglucosamine and the non-denatured type II collagen, the two core components play a complementary role: the N-acetylglucosamine is focused on promoting synthesis of a cartilage matrix and provides a material basis for cartilage repair; the non-denatured type II collagen reduces damage of autoimmune response to cartilage through immunoregulation, the non-denatured type II collagen and the non-denatured type II collagen have a synergistic effect, the symptoms such as arthralgia and swelling can be relieved, the joint structure can be improved from the double angles of repairing and protecting, and particularly the treatment effect on patients with severe osteoarthritis is remarkably superior to that of a single-component preparation; and an innovative and efficient choice is provided for the treatment of osteoarticular diseases.

The invention relates to the technical field of oral non-biological medicine preparations, in particular to an upatinib sustained release tablet and a preparation method thereof. The invention discloses a preparation method of an upatinib sustained-release tablet, and aims to solve the problem that the dissolution rate of the upatinib sustained-release tablet is unstable, namely, the upatinib sustained-release tablet can stably control the release of upatinib in different gastrointestinal tract environments through the synergistic cooperation of all the components of the upatinib sustained-release tablet, and the preparation method of the upatinib sustained-release tablet is relatively low in cost and easy to operate. The large-scale production is facilitated; the upatinib sustained release tablet comprises the following components in percentage by weight: 3.0%-3.5% of upatinib, 18%-19.50% of a pH regulator, 50%-55% of a filler, 17%-22% of an adhesive, 0.1%-1% of a flow aid, 1%-2% of a lubricant and 0.01%-10.9% of a coating material.

The invention relates to the field of veterinary drugs, in particular to a veterinary GS-441524 tablet and a preparation method thereof. In the application, the GS-441524 raw material medicine, the filling agent, the disintegrating agent, the lubricating agent and the stabilizing agent are used as raw materials, the combination of mannitol and microcrystalline cellulose is selected as the filling agent, and coating is performed, so that the novel veterinary GS-441524 tablet is prepared, the medicine loss caused by thermal decomposition of API in the tabletting process is reduced, and the uniformity and the stability of the medicine in the tablet are improved.

The present disclosure provides pharmaceutical and nutritional compositions and methods for treating mitochondrial disorders. The present invention relates to a pharmaceutical or nutritional composition comprising a stabilized sulforaphene (e.g., a sulforaphene-cyclodextrin complex) that improves the efficacy, biological activity, and stability of the isolated sulforaphene. The disclosure also includes the use of the stabilized sulforaphene as an effective therapeutic agent for the treatment of mitochondrial disorders, such as mitochondrial myopathy.

The present invention is in the field of transgene delivery to target cells using viral vectors, particularly in the field of gene therapy. We have identified compositions that allow for oral administration of viral particles, particularly adenoviral particles. [Selection diagram] None

Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).

The invention belongs to the technical field of traditional Chinese medicine preparations, and provides a traditional Chinese medicine granule composition based on rhizoma polygonati and a preparation method and application thereof. A three-layer intelligent response structure design is adopted, a 80-300 nm rhizoma polygonati nano core is prepared through an anti-solvent precipitation technology, a calcium alginate gel buffer layer containing probiotic nutritional factors is constructed through an ionic crosslinking technology, a pH response shell layer is prepared through a fluidized bed coating technology, and the release rate lt in gastric juice is achieved; the cumulative release rate gt in intestinal juice is 10%; according to the invention, the rhizoma polygonati polysaccharide and probiotic nutritional factors are added into the preparation, the precise intestinal targeted release performance is 80%, the drug loading capacity is 15-35%, the coating efficiency is 85-95%, and the technical problems that a traditional rhizoma polygonati preparation is poor in stability, effective components are damaged by gastric acid, and the bioavailability is low are solved; the traditional Chinese medicine composition can be used for treating diseases such as weakness of the spleen and the stomach, functional dyspepsia and dysbacteriosis of intestinal flora, and has wide application value.

The invention belongs to the technical field of medicines, and particularly relates to a melogabalin besylate orally disintegrating tablet coated with powder. The powder-coated melogabalin besylate orally disintegrating tablet provided by the invention has good wet stability, effectively masks the bitter taste of the raw material medicines, obviously improves the taste, has good dissolution behavior, shows extremely rapid dissolution in key media, is beneficial to the absorption of melogabalin besylate by the body, and can be used for preparing the oral disintegrating tablet for treating melogabalin besylate. The melogabalin besylate orally disintegrating tablet provided by the invention has a good application prospect.

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.